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Abstract
The solution structure and dynamics of the BRCT domain from human DNA polymerase μ,
implicated in repair of chromosome breaks by nonhomologous end joining (NHEJ), has been
determined using NMR methods. BRCT domains are typically involved in protein—protein
interactions between factors required for the cellular response to DNA damage. The pol μ BRCT
domain is atypical in that, unlike other reported BRCT structures, the pol μ BRCT is neither part of
a tandem grouping, nor does it appear to form stable homodimers. Although the sequence of the pol
μ BRCT domain has some unique characteristics, particularly the presence of > 10% proline residues,
it forms the characteristic αβα sandwich, in which three alpha helices are arrayed around a central
four-stranded β-sheet. The structure of helix α1 is characterized by two solvent-exposed hydrophobic
residues, F46 and L50, suggesting that this element may play a role in mediating interactions of pol
μ with other proteins. Consistent with this argument, mutation of these residues, as well as the
proximal, conserved residue R43, specifically blocked the ability of pol μ to efficiently work together
with NHEJ factors Ku and XRCC4-ligase IV to join noncomplementary ends together in vitro. The
structural, dynamic, and biochemical evidence reported here identifies a functional surface in the pol
μ BRCT domain critical for promoting assembly and activity of the NHEJ machinery. Further, the
similarity between the interaction regions of the BRCT domains of pol μ and TdT support the
conclusion that they participate in NHEJ as alternate polymerases.
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NOTE ADDED IN PROOF
Coordinates for the pol μ BRCT domain determined as part of the Riken structural genomics consortium also have recently been deposited
in the Protein Data Bank (2DUN). The structures are in close agreement, with the backbone rmsd over the structured region (V30–E124)
of 1.27 Å.
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(1) 1H–15N HSQC spectrum of pol μ BRCT domain, (2) results from light scattering experiments to assess the monomeric/oligomeric
state of the pol μ BRCT domain, (3) 1H 1D spectra of WT, F46A, L50A, and R43A BRCT variants, and (4) an overlay of the pol μ BRCT
domain with the C-terminal BRCT domain of XRCC1. This material is available free of charge via the Internet at http://pubs.acs.org.
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DNA polymerase μ (pol μ) is a recently identified X-family polymerase that includes both a
catalytic and a BRCA1 C-terminal homology (BRCT1) domain (1,2). The sequence of the
enzyme is most similar to terminal deoxynucleotidyltransferase (TdT), with which it shares
41% sequence identity. TdT, pol μ, and pol λ (another, more distantly related pol X family
member) have all been implicated in the nonhomologous end joining (NHEJ) pathway for
repair of double strand breaks (DSBs) (3–7). These three polymerases provide this pathway
with an apparent gradient of template strand dependence (TdT < pol μ < pol λ) (8), in keeping
with the different roles NHEJ must play during V(D)J recombination (8,9) and general repair
of double strand breaks (10).
All pol X members linked to NHEJ, including the sole pol X member in S. cerevisiae, possess
an N-terminal BRCT domain required for a protein—protein interaction with the NHEJ ligase
complex (XRCC4-ligase IV) (6,11). Another NHEJ factor, Ku, can then recruit both XRCC4-
ligase IV and pol X members to DNA ends (5,8). The BRCT domains were determined to be
essential for NHEJ activity both in vitro (3–5) and in cells (8). The three polymerases also
compete with each other to form complexes with NHEJ factors in vitro (6,8) and in cells (8,
9), suggesting the three different BRCT domains interact with the same surface.
The BRCT domain is an abundant structural unit (12,13) found in more than 1000 proteins
from all biological kingdoms. Structurally, it is typically an αβα sandwich, characterized by
four parallel β strands forming a central β-sheet and flanked by three α-helices (14–19). Nearly
all of the proteins containing this motif are involved in the cell cycle checkpoint response to
damaged DNA and/or more directly in DNA replication or repair.
BRCT domains most often function as protein binding domains; e.g. XRCC1, a protein
involved in repair of single-stranded DNA breaks, binds DNA ligase III via its C-terminal
BRCT domain (20), whereas its N-terminal BRCT domain specifically binds poly(ADP-
ribose) polymerase (21). Recently, it has been shown that many BRCT domains possess a
phosphoserine-specific, protein binding function (22–25). Despite the structural homology
observed among BRCT domains, the modes of interaction with known ligands vary widely.
For example, the DNA binding domain of p53 contacts α3 of the N-terminal BRCT domain
from p53-binding protein 1, 53BP1 (14,15). Alternatively, BRCA1 tandem BRCT domains
use residues from α1 and other regions to form a structural unit that specifically binds to a
phosphoserine-containing sequence in the protein BACH1 (26–28). Hence, despite
conservation of the three-dimensional structure of each domain, the mechanism by which
BRCT domains execute their function differs significantly within the BRCT superfamily. In
order to better understand the biological role of pol μ, we have investigated the structural and
dynamic behavior of its BRCT domain. The resulting structure provides useful clues regarding
the regions of interaction with other proteins. One surface on the pol μ BRCT domain was
investigated for its functional role in complex formation with Ku and XRCC4-ligase IV, as
well as in end-joining. Further, a comparison with the recently determined structure of the
BRCT domain derived from TdT (PDB ID 2COE, Nagashima, et al., unpublished) supports
the conclusion that the two proteins may target similar structures and thus work as alternate
polymerases in the NHEJ repair complex.
1Abbreviations: NHEJ, nonhomologous end joining; DSB, double strand break; BRCT, BRCA-1 C-terminal; TdT, terminal
deoxynucleotidyltransferase; NOE, nuclear Overhauser effect; CSI, chemical shift index; RDCs, residual dipolar couplings; RMSD, root-
mean-square deviation.
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Protein Expression and Purification
The polymerase μ BRCT domain gene was subcloned into a pET-28a vector and transformed
into BL21(DE3) E. coli. The 105 residue BRCT domain construct contained residues 21–124
of the full length protein with an additional Gly at the N-terminus. To increase expression, the
first 12 codons were optimized for expression in E. coli. Cells were grown in M9 media
with 15NH4Cl as the sole nitrogen source, and U-13C glucose as the carbon source for doubly
labeled preparations. Cultures were grown to an OD600 of 0.6–0.8 at 37 °C and then cold-
shocked on ice for 5 min. IPTG was added to a final concentration of 400 μM to induce
expression, and culture growth was continued for 5 h at 22 °C. Cells were harvested by
centrifugation for 20 min at 6400g and the pellets resuspended in 40 mL of 25 mM Tris-HCl,
5 mM DTT, pH 8.0.
Cell slurries were subjected to three rounds of freeze–thaw, followed by no more than five 3-
min rounds of sonication at a 30% duty cycle. Cell debris was removed by centrifugation for
30 min at 23 000g, and the supernatant was dialyzed overnight against 25 mM Tris-HCl, 5 mM
DTT, pH 7.9. The lysate was then fractionated over SP-fast flow sepharose (Pharmacia), and
the BRCT domain was eluted with 150 mM NaCl. The protease inhibitor AEBSF (Roche) was
added to the eluted protein at the maximum recommended concentration (1 mg/mL) in order
to limit proteolysis during the extended periods of data accumulation. BRCT was then purified
to 99% over a G-75 superdex (GE-Amersham) column. The concentrated eluate was dialyzed
overnight at 4 °C against NMR buffer (25 mM d-Tris-HCl, 50 mM KCl, 0.02% NaN3, 5 mM
DTT, pH 7.9). The final protein concentration was 0.5 mM.
NMR Chemical Shift Assignments
Most NMR experiments were carried out using a Varian 600 MHz INOVA spectrometer,
equipped with a 5 mm Varian 1H{13C,15N} Cold Probe. Backbone amide residual dipolar
couplings (RDCs) were measured using a Varian 800 MHz INOVA spectrometer, also
equipped with a 5 mm Varian 1H{13C,15N} Cold Probe. All the NMR experiments were
performed at 10 °C. Proton chemical shifts were referenced to internal DSS at 0.00 ppm, and
the heteronuclear chemical shifts were referenced based on the ratio of heteronuclear and
proton gyromagnetic ratios (29). The NMR data were processed with NMRPipe (30), and the
spectra were assigned with NMR-View (31).
Unless stated otherwise, all NMR experiments were implemented using Varian’s BioPack
pulse sequences. The sequential backbone and Cβ chemical shifts were assigned from a
combined analysis of HNCA (32,33), HNCACB (34,35), CBCA(CO)NH (36,37), and HNCO
(32,34) experiments. Several proline backbone resonances were assigned using HCA(CO)N
(38) and the HACAN (39) experiments.
Most side-chain chemical shifts, including prolines, were assigned from a combined analysis
of H(CCO)NH–TOCSY and (H)C(CO)NH–TOCSY experiments (40–42). Both TOCSY
experiments were acquired at two different mixing times, i.e., 12.1 and 18.2 ms, using a 13C
spin-lock field of 9 kHz. Additional side-chain chemical shifts were assigned from a combined
analysis of BioPack HCCH–TOCSY (43) and 3D 15N-separated NOESY (44) experiments.
The 13C isotropic mixing time in the HCCH–TOCSY experiment was 12.1 ms using a 13C
spin-lock field of 9 kHz. Phenylalanine and tyrosine Hδ, Cδ, Hε, and Cε and tryptophan Hδ1
and Cδ1 chemical shifts were assigned from a combined analysis of (HB)CB(CGCD)HD, (HB)
CB(CGCDCE)HE (45), and 1H-13C HSQC experiments. All chemical shift assignments have
been deposited into the BMRB (http://www.bmrb.wisc.edu) as entry 7259.
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All backbone amide chemical shifts, except those of T21, S42, C62, S63, S64, and C119 were
assigned. The amide nitrogen, Hα, and Cα shifts of T21 were assigned from a combined analysis
of HCA(CO)N and HACAN spectra. The side-chain chemical shifts of T21 were assigned from
the HCCH–TOCSY spectrum. The side-chain chemical shifts of S42, S64, and C119 were
assigned from CBCA(CO)NH, (H)C(CO)NH, H(CCO)NH, and HCCH–TOCSY spectra. We
were not able to assign any C62 or S63 chemical shifts, possibly indicating intermediate
conformational exchange for the loop containing these residues. The 105-residue BRCT
domain has 10 proline residues, including 3 diproline stretches. Among the proline residues,
only P96 was completely unassigned. The Cβ, Hβ, Cδ, and Hδ chemical shifts of P91, preceding
P92, were assigned from 3D NOESY and HCCH–TOCSY data. Ninety-one percent of the
proton chemical shifts were assigned for the structure calculation using CYANA.
NOE Experiment
NOE cross-peaks were assigned from a version of the CN–NOESY–HSQC experiment (46)
obtained from Lewis Kay, using a 100 ms mixing time. In this NOESY experiment, the 13C
carrier frequency was set to 67.0 ppm to observe NOEs to both aromatic and aliphatic protons,
facilitating the assignment of NOEs involving aromatic protons. The CN–NOESY–HSQC was
obtained in 90% H2O/10% D2O to observe NOEs from amide protons.
Measurement of Residual Dipolar Coupling Constants
Backbone amide 1H–15N residual dipolar couplings (RDCs) were measured using a spin state
selective HSQC experiment (47), implemented in BioPack. The alignment medium for the
anisotropic phase contained C8E5 (alkyl-poly(ethylene glycol)) and n-octanol in a molar ratio
of 0.87 and C8E5 to buffer ratio of 2.5 wt % (48) in the same buffer used to make the isotropic
measurements. The alignment medium produced a 16.2 Hz 2H quadrupolar splitting of the
HDO resonance. A total of 76 RDCs were unambiguously assigned, ranging in values from
−11.2 to 8.8 Hz.
Structure Calculations
Preliminary structures were generated using CYANA 2.1 and its automated NOE assignment
algorithm (49,50). The new iterative option was used to improve the calibration of NOE cross-
peaks in the presence of weak noise peaks. No additional manual NOEs or hydrogen bond
restraints were used in the calculation. The chemical shift tolerances were set to 0.040, 0.030,
and 0.45 ppm, corresponding to the indirectly detected proton, the directly detected proton,
and the heteronuclear chemical shift dimensions in the 3D NOESY HSQC spectra. In CYANA,
the number of initial structures in each cycle was set to 100 and the number of final structures
set to 20. The number of torsion angle dynamics steps was set to 10000. A total of 147 φ and
ψ dihedral angle restraints were also used in the calculation. The dihedral angle restraints were
set to a range of ±2 times the standard deviation or at least ±20% about the average values
predicted by TALOS (51). CSI predictions were used for angles that did not meet TALOS
acceptance criteria. The angles were set to φ = −70(±50) and ψ = −50(±50) for the alpha helices
and φ = −140(±60) and ψ = +130(±90) for the beta strands. Initially, CYANA assigned 1494
NOEs; 13 of these NOEs were incorrectly assigned because of degeneracies in the chemical
shifts of P22/P23 and P114/P116. A second calculation was performed without the proton
assignments of residues P3 and P4. In this calculation, CYANA assigned 1503 NOEs.
The final 20 CYANA structures from the second CYANA calculation were subjected to a
single round of water refinement using the ARIA 2.0a/CNS 1.2 program (52–54). The CYANA
upper limit NOE restraints were converted to CNS restraints using CcpNmr Format Converter
(55). Three additional NOEs between beta strands 1 and 2, and 42 additional hydrogen bond
restraints (two restraints per hydrogen bond, corresponding to 21 H-bonds), inferred from
TALOS predictions of the locations of the α helices, were also included in the refinement. In
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addition to the distance and dihedral angle restraints, 48 backbone amide RDC restraints were
used in the refinement. Only RDC values for residues in regions of secondary structure were
included. The error in measurement of the RDCs was estimated to be ±0.8 Hz. The molecular
alignment tensor was estimated by fitting the RDCs to the NMR structures obtained from the
CYANA calculation without RDC restraints (56). The initial alignment tensor had a magnitude
(Da) of 3.1 Hz and a rhombicity (R) of 0.6. Upon refinement, the alignment tensor had a
magnitude of 8.7 Hz and a rhombicity of 0.6. The ten lowest energy structures and the average
energy-minimized structure have been deposited into the PDB (ID 2HTF). All CYANA and
ARIA restraints have also been deposited into the PDB.
Relaxation Spectra and Analysis
15N relaxation spectra were collected on U-15N pol μ BRCT domain at 500 and 600 MHz using
standard experiments (57) with the addition of two high-power 1H saturation pulses (2–4 ms)
at the start of the T1 relaxation delay to ensure 1H saturation for early T1 relaxation
periods. 15N T1 data were collected with relaxation delays of 39, 109, 194, 299, 414, 544, 689,
839, and 1004 ms. 15N T2 data were collected with relaxation delays of 8,16, 24,40,63,79,95,
111, and 127 ms. Uniform uncertainties were calculated on the basis of duplicated time points
(underlined above). {1H}–15N heteronuclear NOE spectra were obtained using a saturation
period of 4.5 s, with error calculated from baseplane noise. Decay rates were fit to peak
intensities using expfit2 (in-house written software).
Lipari-Szabo dynamics parameters (58) were fit to decay rates using in-house software relxn2.2
and graphical interface relaxvi. Global fitting of data from rigid residues indicated a τm of 10.5
ns. Using this value, order parameters were fit using the standard model-free formalism for all
residues, with errors assessed on the basis of 150 Monte Carlo simulations. Model selection
based on the Bayesian Information Criterion (BIC) was then applied (59). In cases where the
BIC did not unambiguously identify an optimal model, preference was given to the model with
the fewest parameters or to model 2 (standard model-free), except for residues which were
known not to produce reasonable parameter values in model 2 fits. In these cases model 3 was
applied.
Analysis of Mutant Proteins
The “quick change” (Stratagene) method was used to make mutant pol μ constructs, both in
the context of the isolated BRCT domain (construct described above), as well in the context
of the full length cDNA (6). Mutant BRCT domains were expressed and purified as described
above. Full length constructs (wild type and BRCT substitution mutations) and the ΔBRCT
(Δ21–127)-construct were expressed and initially purified on a 1 mL HiTrap Nickel column
as previously described (6), except instead of subsequent purification using an S200 column,
the HiTrap Nickel column eluent was directly loaded onto a 1 mL HiTrap heparin column, and
bound protein eluted using a buffer containing 25 mM Tris-HCl pH 8.0, 700 mM KCl, 10%
glyercol, and 1 mM DTT. An ultracel 30K (Amicon) centrifugal filtration unit was then used
to concentrate and adjust the salt of heparin column eluents to 250 mM KCl. Ku and XRCC4-
ligase IV complex were purified from baculovirus infected cells as previously described (60).
Intrinsic catalytic activity, as reported in Table 2, was determined using gap filling assays on
a 40 bp DNA duplex with a centrally located single nucleotide gap in one strand (template C)
that has been previously described (7). Reactions were performed with 5 nM of the various pol
μ variants, 20 nM DNA substrate, and a buffer containing 25 mM Tris HCl pH 7.5, 50 mM
NaCl, 50 mM KCl, 1 mM DTT, 5 mM MgCl2, and 25 μM of each dNTP, for 10 min at 37 °C,
and analyzed on a 10% denaturing polyacrylamide gel. The standard deviation from replicate
assays were found to be within 25% of the mean for all six constructs.
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Electrophoresis mobility shift assays (EMSA) were performed using 100 nM of a 60-bp double-
stranded (ds) DNA substrate made by annealing 5′ phosphorylated DAR166 (5′-
CAGCTGGGAATTCCATATGAGTACTGCAGATGCACTTGCTCGATAGAT
CTAACATGAGCC-3′) to DAR167 (5′Cy5-
GTAGGGCTCATGTTAGATCTATCGAGCAAGTGCATCTGCAGTACTCATATGGAA
TTCCCAGCTGAG-3′). This oligonucleotide duplex was incubated with 25 nM Ku for 5 min
in a buffer containing 25 mM Tris-HCl pH 7.5, 150 mM KCl, 13% (wt/vol) glycerol, 1% (wt/
vol) poly(ethylene glycol) (molecular mass, greater than 8000 kD; PEG), 1 mM DTT, and 0.5
mg/mL bovine serum albumin (BSA), followed by addition of 100 ng of uncut plasmid DNA,
50 nM XRCC4-ligase IV complex, and 100 nM polymerase μ before an additional incubation
for 10 min on ice. Resulting DNA–protein complexes were separated by eletrophoresis on a
3.5% polyacrylamide gel in a buffer containing 30 mM Tris-borate (pH 8.2) and 0.3 mM EDTA
(1/3X TBE) and detected using a typhoon fluorescent imager (GE Biosciences).
The NHEJ assay employed a 300 bp substrate with the indicated end structures prepared as
previously described (8), except substrates were fluorescently labeled by synthesis in a mix of
100 μM each dNTP supplemented with 10 μM Cy5 labeled dCTP (GE Biosciences). End-
joining assays were performed by preincubating for 5 min on ice 25 nM pol μ, 25 nM Ku, 50
nM XRCC4-ligase IV, and 5 nM DNA substrate in a buffer containing 25 mM Tris pH 7.5, 75
mM NaCl, 75 mM KCl, 1 mM DTT, 30 μg/mL BSA, 3% glycerol, 0.1 mM EDTA, 12.5%
PEG, and 1 μg of uncut plasmid DNA. Reactions were then supplemented with 25 μM of each
dNTP and 5 mM MgCl2, incubated at 37 °C for 10 min, deproteinized, and subjected to
electrophoresis on a nondenaturaing 5% polyacrylamide gel. Substrate and product species
were detected using a Typhoon fluorescent imager and quantified using ImageQuant total lab
software (GE biosciences).
RESULTS
Assignments and Secondary Structure
The 1H–15N HSQC spectrum of the BRCT domain (Supporting Information, Figure S1) was
unchanged for several weeks at 10 °C, allowing all of the assignment and NOESY experiments
to be carried out on a single U-[13C, 15N]-labeled sample. The spectrum was consistent with
a well-folded isolated BRCT domain, in which most of the amide resonances could be observed
(Figure S1). Details of the chemical shift assignments are discussed in Experimental
Procedures.
A CSI (61) analysis of the Hα, Cα, Cβ, and C′ chemical shifts revealed four beta strands and
three alpha helices (Figures 1 and 2). A TALOS analysis of the same chemical shifts identifies
a fourth short helix near the C-terminus of the domain. Although the existence of the fourth
helix is supported by sequential dNN(i,i+1) NOEs between residues R120–R122 and a dαN(i,i
+3) NOE between C119 and R122, the helix does not appear in the average energy-minimized
structure but appears as a 310-helix in only a few structures of the ensemble (see below) and
is not included in Figures 1–6. Since the four beta strands form a parallel β sheet, many cross-
strand NOEs involving Hα protons were obscured by the water resonance. Consequently, no
manually assigned NOEs or hydrogen bond restraints involving the beta strands were included
in the structure calculation and refinement. The beta strands from the average energy-
minimized structure are composed of residues A31–L34, R57–V58, H68–M71, and L99–
D101. The alpha helices are composed of residues R41–K54, A76–A88, and S103–A111. The
final locations of the secondary structure elements from the average energy-minimized
structure of the 10 lowest energy structures are in good agreement with the TALOS predictions
and are shown in Figure 1.
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A superposition of the ten lowest energy structures obtained after water refinement is shown
in Figure 2A, and the average energy-minimized structure obtained from these 10 structures
is shown in Figure 2B. The ten structures superimpose with backbone and heavy atom RMSDs
of 0.70 Å and 1.08 Å, respectively, for residues 30–124. The N-terminal residues, 20–29, are
disordered. A compilation of the structural statistics for the ten lowest-energy structures is
shown in Table 1. The solution structure of the BRCT domain of pol μ consists of a central
four-stranded parallel β sheet, flanked by helices α1 and α3 on one face of the β sheet, and
helix α2 on the opposing face of the β sheet (Figure 2B). Several members of the ensemble of
structures have a short 310-helix comprising residues C119–R122 that is consistent with the
TALOS predictions and the sequential and intermediate NOEs (see above). It is possible that
this region forms a stable 310-helix in solution; however, there were insufficient NOEs to define
it in all members of the ensemble in this study. This region of the domain interacts with β4 at
the edge of the β sheet via a hydrogen bond between the backbone carbonyl of H121 and the
backbone amide of D101. The topology of the BRCT domain (Figures 2A and 2B) is common
to other BRCT domains, such as the BRCT domain of XRCC1 (19) and the C-terminal BRCT
domain of BRCA1 (62).
Several residues near the N-terminus of α1 appear slightly disordered. These residues include
R41, S42, R44, and A26. Two of these residues, R41 and R44, show evidence of slow
conformational exchange based on 15N relaxation analysis as described below. S42 also shows
evidence of conformational averaging because its amide resonance could not be assigned due
to line-broadening. This conformational averaging of α1 may be important for recognition of
other NHEJ proteins as discussed below. We have previously noted a similar, although more
extreme effect for helix α3 in the protein θ, a subunit of E. coli DNA polymerase III (63). This
characteristic made it difficult to determine the solution structure of θ, and the more extreme
exchange broadening of resonances corresponding to this helix was ultimately dealt with by
varying the polarity of the solution (63).
The domain contains a well-defined hydrophobic core. Some of the hydrophobic residues
comprising the core that are conserved between pol μ, pol λ, and TdT are shown in Figure 3A.
In addition, there are four salt bridges on the surface of the molecule to further stabilize the
tertiary structure (Figure 3B). One salt bridge involves residues R43 on α1 and E72 on L3, a
second includes R57 on β2 and E65 on L2, and the third and fourth salt bridges are between
R44 on α1 and E36 on L1 and D60 on L2 (Figure 3B). There are no charged residues in the
hydrophobic core, but there are two solvent-exposed hydrophobic residues on helix α1, F46
and L50, that may be involved in intermolecular interactions (Figure 3B).
Complex Formation and NHEJ Activity
R43, F46, and L50 in particular stand out as both solvent exposed in the pol μ BRCT structure
(Figure 3), and invariant when comparing pol μ and TdT sequences from diverse species
(Figure 1). To address their role in mediating interactions with NHEJ factors, we mutated each
of these residues individually to alanine (R43A, F46A, and L50A), both in the context of the
isolated domain as well as the full length protein. 1H NMR spectra from purified domains with
the more severe mutations (R43A, F46A, and L50A) confirmed these mutations were not
sufficient to globally disrupt domain folding (Supporting Information, Figure S3). 1H 1D
spectra have been recently used successfully for this purpose in the case of a BRCT domain
from replication factor C (16). We also generated the more conservative F46L substitution, as
both pol λ and a recently reported variant TdT BRCT structure (2COE, see Discussion) possess
this substitution. All four full length mutant constructs retained intrinsic synthesis activity
similar to wild type pol μ and pol μ with its BRCT domain entirely deleted (ΔBRCT) (Table
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2). This is consistent with prior work indicating the BRCT domain is required for interations
with NHFJ core factors but not its intrinsic ability to perform synthesis.
We then employed an electrophoretic mobility shift assay to determine whether R43A, F46A,
and L50A remained capable of forming a stable complex with Ku and XRCC4-ligase IV. Under
the conditions used here, Ku alone forms a stable complex on DNA ends, while addition of
XRCC4-ligase IV results in a less stable species of heterogeneous mobility (Figure 4B) (6).
Further addition of wild type pol μ but not a pol μ truncation mutant missing its BRCT domain
(ΔBRCT), generates a much more stable triple complex (Ku, XRCC4-ligase IV, and pol μ) at
DNA ends. Importantly, the amount of triple complex formed with the R43A, F46A, or L50A
mutants is at least 10-fold lower (Figure 4; Table 2). In contrast, F46L-promoted formation of
the triple complex approximately 1/3 as well as wild type pol μ.
Pol μ is uniquely capable of promoting template dependent synthesis from ends aligned by Ku
and XRCC4-ligase IV, even when ends are noncomplementary. A number of catalytic domain
residues required for this activity were recently defined (8,64). We show here that this activity
is also highly dependent on the ability of pol μ to form a stable complex with Ku and XRCC4-
ligase IV: relative to wild type pol μ, the ability of F46L to promote joining of such ends is 3-
fold lower, while activities of the more severe mutants (R43A, F46A, and L50A) are reduced
by 5–10 fold (Figure 4C, Table 2). R43, F46, and L50 thus define residues in pol μ’s BRCT
domain that are critical for the ability of pol μ to make use of interactions with Ku and XRCC4-
ligase IV in order to support template-dependent polymerization.
Conformational Heterogeneity from 15N Relaxation
To gain further insight into BRCT structure and function, a characterization of the dynamics
of pol μ BRCT was initiated using 15N spin relaxation methods (Experimental
Procedures). 15N T1, T2, and 15N—{1H} NOE were measured at 500 and 600 MHz field
strengths and further analyzed using the Lipari-Szabo model-free formalism (58). The
correlation time for overall tumbling of the domain, τm, was determined to be 10.5 ns, consistent
with a monomeric BRCT domain under the conditions used (also, see Discussion for
comparison to previous results). Fitting to an axially symmetric diffusion tensor yielded D||/
D⊥ of 1.1, indicating that tumbling anisotropy has a negligible effect on relaxation. The
monomeric state was independently confirmed using static and dynamic light scattering
(Supporting Information, Figure S2). The dynamic character of the backbone on a per residue
basis is summarized in Figure 5. Overall, the order parameters, S2, corresponding to rigidity
of amide N–H bond vectors on a scale of 0 to 1, are approximately 0.9 in regions of secondary
structure. Regions of structural flexibility are therefore restricted to “loop” regions. Lower
order parameters (higher flexibility) are found in residues 90, 94, and 95 (data on 91–93 were
not obtained), which reside in L4 (Figure 5). While order parameters report on fast ps-ns time
scale motions, flexibility on the, μs-ms time scale can be detected from enhanced transverse
relaxation rates (R2 = 1/T2) or alternatively from line broadening and loss of intensity in 2D
(or nD) peaks due to chemical exchange effects. Figure 5 shows both R2 values and peak
intensities (from the 600 MHz HSQC spectrum). From this it can be seen that residues 35–41
show evidence of “slow”, μs-ms motions; these residues essentially define the LI loop. From
the model selection analysis of the relaxation data, model 3 (S2, τe, Rex) was selected for
residues 35, 36, 39, 44, 47, 67, and 103, with Rex values that varied from 0.4 to 3 Hz. It should
also be added that residues 62–64 (in L2) could not be assigned due to line-broadening, and
so this loop is also flexible or changing conformations on a slow time scale. All of these flexible
residues except for 67 and 103 are in loop regions and correlate well with decreased precision
in the ensemble of structures (Figure 2A).
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We report here the solution structure, dynamics, and biochemical evidence for a functional
surface of the BRCT domain from human polymerase μ This represents a first step toward
understanding how these polymerases interact with the NHEJ machinery.
Structural Comparison to the BRCT Domain from TdT
Two other members of the pol X family of polymerases, TdT and pol λ also have N-terminal
BRCT domains. Pol μ is most similar to TdT, with 41% sequence identity (2) overall and 39%
sequence identity over the BRCT domain (residues V30-E124, see Figure 1). In contrast, the
sequence identity with the pol μ BRCT domain is only 19% over the structured region of the
domain (Figure 1). The residues that are identical between all three domains are shown in red
and highlighted in yellow in Figure 1.
Recently, an NMR solution structure of the BRCT domain of human TdT has been deposited
in the Protein Data Bank (PDB ID 2COE, Nagashima, et al., unpublished). The pol μ and TdT
BRCT domains have the same folding topology, and the lowest energy TdT structure
superimposes on the average energy-minimized pol μ structure with a backbone rmsd of 2.1
Å (Figure 6A). Overall, the structures are very similar, although α2 is shorter in the TdT domain
compared to the μ domain. Since α2 is shorter in TdT, the position of L4, connecting α2 and
β4, in the two domains is different: In the pol μ ensemble of structures, L4 appears more
disordered (Figure 2A), and residues A71, C75, and T76 in L4 exhibit increased backbone
dynamics (Figure 5). L4 is also a region of low sequence conservation (Figure 1).
The positions of many of the hydrophobic and aromatic residues in the two domains are very
similar, such as interactions between Y33 and W82 and W104 and H68 (Figure 6B and
corresponding residues in 6C). Both BRCT domains have exposed hydrophobic residues on
α1 and α2; in pol μ the side chains of F46, L50, and V80 are exposed; in TdT the side chains
of F40, L44, and L74 are exposed (Figures 6B and 6C). Note that a leucine at position 40 of
the TdT structure is inconsistent with a phenylalanine found at this site in both the published
human TdT sequence as well as TdT from other species (see, e.g., Figure 1), suggesting that
leucine is either a rare polymorphism or a mutation that arose during cloning. The solvent
exposure of hydrophobic residues F46, L50, and V80 (and corresponding residues in TdT)
suggested that these residues might mediate interactions with other proteins in the NHEJ repair
complex.
The electrostatic surfaces of the pol μ and TdT BRCT domains are also very similar (Figures
7A–D). Both domains have a ridge of positively charged residues on one face of the protein
(compare Figures 7A and 7C), and large negative regions on the opposite faces of the proteins
(compare Figures 7B and 7C). In the pol μ domain, the positive ridge is composed of residues
R44, R52, R85, and R86, whereas in TdT the ridge is composed of residues R47, R46, R38,
and K31. It is conceivable that this ridge may be an interaction site for phosphopeptide binding.
In the pol μ domain, the ridge is partially obscured by the acidic side chains of residues E36
and D60, which form a salt bridge with R44. However, in TdT the acidic side chains of E30
and E55 are in close proximity to R34, corresponding to R44 in pol μ, and may also form salt
bridges under some conditions.
Comparison to Other BRCT Domains
One of the interesting aspects of the BRCT fold is that it appears to be multifunctional. The
fold accommodates direct binding of both proteins (phosphorylated and nonphosphorylated)
and DNA, and it utilizes a number of different surfaces for different interactions. A variety of
structures of BRCT domains have been determined (65), although the majority of these are of
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tandem repeat BRCT domains, such as in BRCA1 (62), 53BP1 (14), and MDC1 (66). Tandem
repeat BRCTs, in particular, have been shown to bind phospho-peptides (22–28,67). In
addition, other BRCT domains appear to homo- or heterodimerize (68). The pol μ BRCT
structure is atypical in that it appears to be the first reported (in the literature) BRCT domain
structure that is neither part of a tandem grouping nor forms a stable dimer, as demonstrated
here for μ-BRCT by 15N relaxation and light scattering. (It should be mentioned that while
other BRCT domains appear in the PDB as monomeric structures (see below), without
additional measurements, the oligomeric state of these domains remains uncertain).
To assess the degree of structural similarity between pol μ BRCT and individual BRCTs from
tandem or dimerized domains, we carried out a number of backbone superimpositions.
Domains found either in tandem pairs or as noncovalent dimers from BRCA1, XRCC1, 53BP1,
MDC1, and DNA ligase IIIα all superimposed to the energy-minimized μ-BRCT domain with
RMSDs of 5 Å or greater. The sole exception was the C-terminal BRCT domain from the NMR
structure of BRCA1 (1OQA), which has an rmsd of 2 Å if helix α2 is excluded from the
superposition; however, this BRCT domain is structurally different because the α2 helix from
this BRCT domain has only ~1 turn. An example of the different orientation of helix α2 in the
μ-BRCT domain vs the C-terminal BRCT domain from XRCC1 (1CDZ) is shown in
Supporting Information (Figure S4).
Next, we sought to determine the extent of structural similarity between the pol μ BRCT domain
(and hence pol TdT) and BRCT domains in the protein data bank that are not from tandem
pairs or found as dimers. The apparently monomeric BRCT domains found in the PDB include
the NAD+-dependent DNA ligase BRCT domain from T. thermophilus (PDB ID: 1L7B), the
second BRCT domain of epithelial transforming growth factor 2 (PDB ID: 2COU), and the
BRCT domain of poly(ADP-ribose) polymerase-1 (PDB ID: 2COK), which superimpose with
backbone RMSDs of 4.8, 6.3, and 11 Å, respectively. In addition, 2COU, as with 1OQA
(BRCA1) and 1IMO (DNA ligase III), lacks most or all of the α2 helix. In summary, it appears
that the pol μ and TDT BRCT domains have unique structural properties, as indicated by high
rmsd values with other BRCT domains, and that an element of major structural difference
across all BRCT domains is the α2 helix.
Relaxation/Dynamics and Monomeric State of pol μ BRCT
We have performed a standard 15N relaxation analysis of the backbone dynamics of human
polymerase μ. Only two BRCT domains have been previously characterized by 15N relaxation:
the C-terminal BRCT domain from BRCA1 (62) and the BRCT domain from DNA ligase
IIIα (17). Because BRCA1 contains a tandem repeat and DNA ligase IIIα is reported to be a
dimer in solution (17), this study represents the first dynamics characterization of a singly
occurring (nontandem), nondimeric BRCT domain. The correlation time for tumbling, τm, was
determined to be 10.5 ns at 10 °C. We believe that this is consistent with 15N relaxation data
on the dimeric BRCT domain from DNA ligase IIIα, even though that domain was reported to
have a global τm value of 6.82 ns at 15 °C (16). In that same report (16), the average R2 values
were 19.5 s−1 at 15 °C, consistent with a tumbling correlation time of at least 14 ns. This is
reflected in the local τm times reported in Figure 2 of that paper, which are inconsistent with
the global tumbling time cited in the text (16). These considerations lead us to conclude that
the pol μ BRCT is monomeric under the conditions studied here. This has been confirmed by
light scattering experiments (Supporting Information, Figure S2). For the pol μ BRCT domain,
the only region found to have increased flexibility on the ps-ns time scale is L4 (Figure 5). On
the other hand, slower motion on the μs-ms time scale occurs in loops LI and L2.
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Functional Hot Spots in pol μ BRCT Are Proximal to Phospho-Binding Sites in Other BRCT
Domains
Inspection of the solution structure and dynamics of pol μ BRCT allowed identification of the
L1-α1 region as a surface containing residues that are potentially important for function.
Specifically, the hydrophobic side chains F46 and L50 in α1 are conspicuously exposed to
solvent and show high conservation in pol μ and TdT. In addition, R43, also in α1, shows
evidence for flexibility on the μs-ms time scale, along with residues in L1 (Figure 5) that lead
into α1. Because of their spatial proximity and definition of a contiguous surface (Figure 4A),
residues R43, F46, and L50 were mutated to test their importance in NHEJ complex formation
and activity using gel shift assays. Since all of these residues are found to be solvent-exposed
in the pol μ BRCT structure, it was assumed that substitution of any of these residues with
alanine would not result in significant structural changes. These general conclusions were
supported by the 1H spectra of the mutated proteins, which were all consistent with the
expectation of a conserved structure for each of the mutants tested. The assays showed that
mutation of any one of these residues to alanine in the context of full length pol μ largely
abolishes pol μ’s ability to form a stable complex with Ku and XRCC4-ligase IV assembled
on DNA ends. This in turn strongly reduces the ability of pol μ to help Ku and XRCC4-ligase
IV join ends that require prior gap filling before they can be joined. The results of these
experiments demonstrate that the N-terminal region of helix α1, and possibly L1, have a pivotal
role in promoting interactions with the NHEJ machinery that are critical for pol μ’s biological
role.
Interestingly, this general region has been implicated in other BRCT-protein interactions. In
the BRCA1–BACH1 complex, S1655 and G1656, in L1 of the N-terminal BRCT domain, form
hydrogen bonds to the phosphoserine (26–28,67). Nearly identical interactions are formed in
the MDC1–H2AX complex (69). These residues correspond to μ-BRCT residues V35 and E36,
in L1, which experience μs-ms fluctuations (Figure 5). Several lines of reasoning suggest that
the details of functional interactions in μ-BRCT may be different than in the BRCA1–BACH1
or MDC1–H2AX complexes. First, μ-BRCT is not a tandem domain, although it is possible
that it may form heterodimers with other BRCT domains, such as that in XRCC4. Second, L1
in μ-BRCT is composed of nearly twice as many residues as in the N-terminal BRCT domains
of BRCA-1 and MDC1. Third, in the N-terminal region of α1, there are two conserved arginines
(43 and 44). R44 is involved in a salt bridge to the side chain of E36, which resides in the
flexible L1. These two arginines are conserved throughout species of μ and TdT polymerases
(Figure 1), whereas in the N-terminal BRCA1 domain there are no positively charged side
chains in this region and a glutamate at the position corresponding to R43 in μ-BRCT. It is
worth mentioning, however, that in one of the BRCA1–BACH1 crystal structures (1T29), the
carboxyl group of E1661 (equivalent to R43 in μ-BRCT) appears to be involved in an
electrostatic interaction with the side chain of R3 (−3 position) in the BACH1 peptide. This is
consistent with a role for the conserved arginines in μ-BRCT in peptide/protein (or even DNA)
recognition.
In summary, the prominent solvent exposure of hydrophobic residues and evidence for
microsecond-millisecond motions, along with sequence conservation information, has led to
the biochemical identification of a group of spatially proximate residues likely to be important
for protein interactions of the pol μ BRCT domain. The significance of these residues received
strong support from assays performed on mutated analogs of pol μ. In addition, a structural
comparison with the BRCT domain of TdT suggests that this interaction surface is well
conserved, supporting the hypothesis that these polymerases can both be recruited by the NHEJ
repair complex.
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Alignment of pol X BRCT domains. Secondary structure elements (blue cartoons) in the human
pol μ BRCT domain are aligned relative to its amino acid sequence and five other pol X BRCT
domain sequences. Following their names and species, positions are numbered according to
locations in their respective full length proteins. Positions conserved in all six members are
highlighted in yellow. Residues conserved in more than four pol X members are identified in
red (identical) or green (similar). Sequences were aligned using AlignX, a clustalW-based
module of Vector NTI (Invitrogen). The first residue in human pol μ (G20) represents a
substitution relative to the published sequence (S20).
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Solution structure of the BRCT domain of pol μ.. (A) The 10 lowest energy structures after
water refinement superimpose with a backbone rmsd of 0.70 ± 0.12 Å. The alpha helices are
shown in red; the beta strands are shown in cyan. (B) The average, energy-minimized structure
computed from the 10 lowest energy structures is shown. The central β sheet is shown with
α1 and α3 packed against one side of the sheet and α2 packed against the opposite side of the
sheet.
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Structurally important residues of the BRCT domain of pol μ Positions of fully conserved
residues, salt bridges, and exposed hydrophobic residues of the BRCT domain of pol μ (A)
The average, energy-minimized structure is depicted with the side chains of residues that are
fully conserved between, pol μ, TdT, and pol λ. The conserved residues H68, V70, L99, W104,
L105, and V115 form part of the hydrophobic core of the domain. (B) The side chains of
arginine, aspartate, and glutamate residues involved in salt-bridge formation and the exposed
hydrophobic residues, F46 and L50 are shown.
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Activity of pol μ BRCT domain mutants. (A) A surface representation of the pol μ BRCT
domain, with the solvent exposed area of R43, F46, and L50 highlighted in green. (B) EMSA
analysis was performed in the presence of a 60 bp DNA duplex, Ku, XRCC4-ligase IV (X4-
LIV), and full length wild type pol μ (wt), pol μ with the BRCT domain deleted (ΔBRCT), or
full length pol μ with BRCT domain substitution mutations as noted. The composition of each
species of distinct mobility has previously been determined (Mahajan MCB 2002) and is noted
with cartoons at the left of the panel. (C) Joining of a 300 bp substrate with two nucleotide TT
3′ overhangs was performed in the presence of Ku, XRCC4-ligase IV, and various pol μ
constructs as noted. S denotes substrate, and P denotes joined concatemer products.
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Regions of flexibility in the BRCT domain of pol μ. Backbone flexibility by three different
measures are shown as a function of residue number. The 15N transverse relaxation rate, R2,
is shown in filled circles. Increases from the mean are indicative of “slow” motions on the μs-
ms time scale. These rates are typically inversely proportional to the intensity of peaks in
a 1H–15N HSQC, as shown in the filled triangles. Lipari-Szabo model-free order parameters,
S2, are shown in open circles. S2 can take on values from 0 to 1, with 0 corresponding to the
limit of complete flexibility and 1 corresponding to complete rigidity of an N–H bond vector.
Order parameters report on motion on the ps-ns time scale.
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Comparison of pol μ and TdT BRCT domains. (A) The average, energy-minimized structure
of the BRCT domain of polμ (cyan) and the BRCT domain of TdT (yellow, PDB ID 2COE
model 1) superimpose with a backbone rmsd of 2.1 Å. (B, C) The positions of the aromatic
side chains in the hydrophobic core are conserved between the two domains, as well as the
positions of exposed hydrophobic residues on 1 and 2.
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Electrostatic surfaces of the BRCT domains of pol μ and TdT. (A) A ridge of positively charged
residues on the surface of the BRCT domain of pol μ may be the site of phosphopeptide or
DNA binding. (B) Electrostatic surface of the BRCT domain of pol μ rotated 180° about the
vertical direction with respect to part A, showing a large patch of negatively charged residues.
(C) As in the pol μ domain, a ridge of positively charged residues on the surface of the TdT
domain may be the site of phospho-peptide or DNA binding. (D) Electrostatic surface of the
BRCT domain of TdT rotated 180° about the vertical direction with respect to part C, showing
a large patch of negatively charge residues.
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Table 1




 medium range (i, i ± 2–4) 126
 long range (i, i > 4) 661
 total 1506
 H-bond restraints (two per H-bond) 42
RDCa
 RMS error (Hz) 0.91 ± 0.17
 R-factorb 7.6% ± 1.6%
 Pearson’s r 0.98 ± 0.006
ensemble rmsd(Å)
 backbone (residues 30–124)d 0.70 ± 0.12
 heavy atoms (residues 30–124)d 1.08 ± 0.11
average violations per structure
 NOEs and H-bonds 1.4 ± 0.5
 dihedrals 2.6 ± 0.9
rmsd (experimental restraints)c
 NOEs (Å) 0.0537 ± 0.0078
 H-bonds (Å) 0.0126 ± 0.0078
 dihedral angles (deg) 1.29 ± 0.25
rmsd (covalent geometry )c
 bonds (Å) 0.0042 ± 0.0001
 angles (deg) 0.5910 ± 0.0195
 impropers (deg) 1.9041 ± 0.1779
Ramachandran space (%)e
 most favored region 85.0 ± 2.8
 additionally allowed 13.0 ± 2.9
 generously allowed 1.4 ± 1.1
 disallowed 0.5 ± 0.7
a
The range of dipolar couplings was −11.2 to +8.8 Hz. The error in the RDCs was ±0.8 Hz.
b
Calculated as described by Clore and Garrett (70).
c
Output by ARIA (54), calculated by CNS (52) using the ensemble of the ten lowest energy structures.
d
Average backbone rmsd of all structures with respect to the mean calculated with MOLMOL (71).
e
Calculated with PROCHECK (72,73). The percentages are computed over all seven lowest energy structures.
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Table 2
Activities Relative to Wild Type pol μ
intrinsic with Ku + XRCC4-ligase IV
polymerase % gap filla % complexb % joiningc
wild type 100 100 100
pol μ ΔBRCT 120 <10 1
R43A 110 <10 20
F46A 110 <10 7
F46L 120 35 34
L50A 120 <10 19
a
Gap filling activity, relative to wild type full length pol μ (100%) determined on a gapped duplex substrate without Ku and XRCC4-ligaseIV(see
Experimental Procedures).
b
Amount of polymerase + Ku + XRCC4-ligase IV complex formed, relative to that seen with wild type full length pol μ (100%), determined by EMSA
in Figure 4B.
c
End joining activity, relative to wild type full length pol μ (100%), determined in the presence of Ku and XRCC4-ligase IV in Figure 4C.
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